Pliant Therapeutics to Participate in the 40th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Pliant Therapeutics, a clinical stage biotechnology firm focused on fibrosis treatments, announced that its CEO, Bernard Coulie, will present a company update at the 40th Annual J.P. Morgan Healthcare Conference.

The virtual presentation is scheduled for January 12, 2022, at 9:45 a.m. ET. Access is available via the Investor Relations' Events page on Pliant's website, with a replay option for 30 days post-event.

Pliant's lead candidate, PLN-74809, is in Phase 2a trials for idiopathic pulmonary fibrosis and primary sclerosing cholangitis.

SOUTH SAN FRANCISCO, Calif., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer of Pliant, will present a company update as part of the 40^th Annual J.P Morgan Healthcare Conference. The virtual presentation will begin on Wednesday, January 12, 2022, at 9:45 a.m. ET /6:45 a.m. PT.

Interested parties can access this presentation from the Investor Relations’ Events & Presentation page of Pliant’s website at https://ir.pliantrx.com/news-and-events/events-and-presentations with an replay available for 30 days following the conclusion of the event.

About Pliant Therapeutics, Inc.

Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small molecule dual selective inhibitor of α_vß₆ and α_vß₁ integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both IPF and PSC. Pliant is currently recruiting Phase 2a trials of PLN-74809 in the lead indications of IPF and PSC. Pliant has also developed PLN-1474, a small molecule selective inhibitor of α_vß₁ for the treatment of nonalcoholic steatohepatitis, or NASH with liver fibrosis, which Pliant has transferred to Novartis pursuant to our development partnership. In addition to clinical stage programs, Pliant currently has two preclinical programs targeting oncology and muscular dystrophies. For additional information about Pliant Therapeutics, visit www.pliantrx.com and follow us on Twitter, LinkedIn, Facebook and YouTube.

Investor and Media Contact:

Christopher Keenan
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.
ir@pliantrx.com

FAQ

What is the date and time of Pliant Therapeutics' presentation at the J.P. Morgan Healthcare Conference?

Pliant Therapeutics' presentation is scheduled for January 12, 2022, at 9:45 a.m. ET.

Where can I access the Pliant Therapeutics presentation?

The presentation can be accessed on Pliant's Investor Relations' Events page.

What is PLN-74809 and what are its indications?

PLN-74809 is an oral small molecule being developed for idiopathic pulmonary fibrosis and primary sclerosing cholangitis.

Has PLN-74809 received any designations from the FDA?

Yes, PLN-74809 has received Orphan Drug Designation from the FDA for both idiopathic pulmonary fibrosis and primary sclerosing cholangitis.

What phase are the clinical trials for PLN-74809 currently in?

PLN-74809 is currently in Phase 2a trials for its lead indications.